Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorImmune Oncology Research Institute

About this trial

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Eligibility criteria

Qualifiers

Diagnosis of BPDCN

Signed informed consent form for prospective patients

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

22
Armenia
Hematology Center named after prof. R. Yeolyan0014, Yerevan Armenia
Canada
University of CalgaryT2N 1N4, CalgaryAlberta, Canada
Children's Hospital of Eastern Ontario, University of OttawaK1H 8L1, OttawaOntario, Canada
Cyprus
Cyprus Society of Haematology2019, Nicosia Cyprus

Sponsors and collaborators

Immune Oncology Research Institute

Lead sponsor